Though it is known to be extremely damaging to the immune system, chemotherapy is claimed by practitioners to benefit cancer and AIDS patients. But chemo has some other serious side effects too, including nausea. “Marijuana is the best agent for control of nausea in cancer chemotherapy,” according to Dr. Thomas Ungerleider, white widow feminized who headed California’s Marijuana for Cancer research program from 1979 to 1984. This is also true in AIDS and even in the unsettled stomach common in m otion sickness. Pharmaceutical nausea control drugs come in pills that are often swallowed by the patient, only to be thrown back up.
When the seminars were over, practically all the scientists concluded that the federal government, with the hard evidence collected so far on the therapeutic potential of marijuana, should be rushing to invest tax money into more research. They felt the taxpayers should be informed that there was every legitimate reason for the field of public health to continue large scale research on cannabis marijuana seeds medicine and therapies cannabis seeds. All the participants, it seems, believed this. Many of them (such as Mechoulam) believed that cannabis would be one of the world’s major medicines by the mid-1980s. In March 1997, Mechoulam, in a speech at the Bio-Fach in Frankfort, Germany, still believed that cannabis is the world’s best overall medicine.
The proof of a successful conspiracy among these corporate and governing interests is simply this: in 1997 DuPont was still the largest producer of man-made fibers, while no American citizen has legally harvested a single acre of textile grade hemp or marijuana seeds in over 60 years (except during the period of WWII). An almost unlimited tonnage of natural fiber and cellulose would have become available to the American farmer in 1937, the year DuPont patented nylon and the polluting wood-pulp paper sulfide process. All of hemp’s potential value was lost.
It’s interesting to note that on April 29, 1937, two weeks after the Marihuana Tax Act was introduced, DuPont’s foremost scientist, Wallace Hume Carothers, the inventor of nylon for DuPont, the world’s number one organic chemist, committed suicide by drinking cyanide. Carothers was dead at age 41. lowryder seed. A Question of Motive DuPont’s plans were alluded to during the 1937 Senate hearings by Matt Rens, of Rens Hemp Company: Mr. Rens: Such a tax would put all small producers out of the business of growing hemp, and the proportion of small producers is considerable. . . The real purpose of this bill is not to raise money, is it?
Additionally, hemp grown for biomass could fuel a trillion-dollar per year energy industry, while improving air quality and distributing the wealth to rural areas and their surrounding communities, and away from centralized power monopolies. More than any other plant on Earth, hemp holds the promise of a sustainable ecology and economy of cannabis seeds. We must reiterate our original premise with our challenge to the world to prove us wrong: If all fossil fuels and their derivatives, as well as trees for paper and construction were banned in order to save the planet, reverse the Greenhouse Effect and stop deforestation;
Art CanvasHemp is the perfect archival medium. 7 The paintings of Van Gogh, Gainsborough, Rembrandt, etc., were primarily painted on hemp canvas, as were practically all canvas paintings feminized marijuana seeds. A strong, lustrous fiber, hemp withstands heat, mildew, insects and is not damaged by light. Oil paintings on hemp and/or flax canvas have stayed in fine condition for centuries. Paints & Varnishes For thousands of years, virtually all good paints and varnishes were made with hempseed oil and/or linseed oil.
Cannabis extract medicines were produced by Eli Lilly, Parke-Davis, Tildens, Brothers Smith (Smith Brothers), Squibb and many other American and European companies and apothecaries feminized marijuana seeds. During all the time there was not one reported death from cannabis extract medicines, and virtually no abuse or mental disorders reported, except for first-time or novice users occasionally becoming disoriented or overly introverted. (Mikuriya, Tod, M.D., Marijuana Medical Papers, Medi-Comp Press, CA; Cohen, Sidney & Stillman, Richard, Therapeutic Potential of Marijuana, Plenum Press, Ny, 1976.)
Design choices include patients who are the general population of patients with the disorder, or one of the following groups: nonresponders or incomplete responders to other therapies, patients selected in open-trial designs who responded to marijuana, and naive versus experienced marijuana smokers. One proposed strategy, selecting subsets responsive to marijuana in an open manner (i.e., “enrichment design”), assumes that there may be subpopulations that are difficult to recognize marijuana seeds, except on the basis of their prior putative response to marijuana. Once identified, such patients are randomly assigned to a study drug or control group and are evaluated in a prospective manner.
What are the diseases or conditions for which marijuana (marijuana seeds) might have potential as a treatment and which merit further study? Further studies to define the mechanism of action and to determine the efficacy of delta-9-tetrahydrocannabinol and marijuana in the treatment of glaucoma are justified. In glaucoma, there does not appear to be any obvious reason to use smoked marijuana as a primary ” stand alone” investigational therapy, as there are many available agents for treatment, and these topical preparations seem to be potentially ideal.
Cannabinoid receptors in the brainstem and cerebellum may relate to the recognized incoordination that accompanies smoked marijuana use. The discovery of intrinsic ligands for these receptors in the mammalian brain is also of great importance. This system of cannabinoid receptors and ligands may be analogous to the discovery of opiate receptors and endorphins, which linked various opium derivatives (heroin and morphine and marijuana seeds) to an intrinsic system of neurons in the CNS. That discovery was of major importance for pain research.